Moderna Management
Management criteria checks 3/4
Moderna's CEO is Stephane Bancel, appointed in Oct 2011, has a tenure of 13.17 years. total yearly compensation is $17.07M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 5.48% of the company’s shares, worth $831.22M. The average tenure of the management team and the board of directors is 4.7 years and 10.6 years respectively.
Key information
Stephane Bancel
Chief executive officer
US$17.1m
Total compensation
| CEO salary percentage | 9.2% |
| CEO tenure | 13.2yrs |
| CEO ownership | 5.5% |
| Management average tenure | 4.7yrs |
| Board average tenure | 10.6yrs |
Recent management updates
Recent updates
Moderna: Cutting Costs Might Not Be Enough
Dec 18Here's Why We're Watching Moderna's (NASDAQ:MRNA) Cash Burn Situation
Nov 30
Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store
Nov 22Moderna: Assessing The Impact Of GSK's Patent Lawsuit
Oct 22The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%
Oct 11Moderna: Still Bullish View
Sep 20Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling
Sep 12Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)
Aug 26Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop
Aug 18Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results
Aug 03Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic
Jul 30Moderna: Really Strong Competition
Jun 30Moment Of Truth Approaches For Moderna's RSV Vaccine
Jun 18What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You
Jun 06Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor
May 23Moderna Q1: A Promising Pipeline Is Undervalued
May 15We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed
Apr 30Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares
Apr 22Moderna: Considering The Cancer Vaccine Angle
Apr 11Moderna Continues To Build A Pipeline
Apr 03Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play
Mar 27Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$2b |
| Jun 30 2024 | n/a | n/a | -US$6b |
| Mar 31 2024 | n/a | n/a | -US$6b |
| Dec 31 2023 | US$17m | US$2m | -US$5b |
| Sep 30 2023 | n/a | n/a | -US$3b |
| Jun 30 2023 | n/a | n/a | US$1b |
| Mar 31 2023 | n/a | n/a | US$5b |
| Dec 31 2022 | US$19m | US$1m | US$8b |
| Sep 30 2022 | n/a | n/a | US$12b |
| Jun 30 2022 | n/a | n/a | US$14b |
| Mar 31 2022 | n/a | n/a | US$15b |
| Dec 31 2021 | US$18m | US$990k | US$12b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$3b |
| Mar 31 2021 | n/a | n/a | US$598m |
| Dec 31 2020 | US$13m | US$946k | -US$747m |
| Sep 30 2020 | n/a | n/a | -US$597m |
| Jun 30 2020 | n/a | n/a | -US$488m |
| Mar 31 2020 | n/a | n/a | -US$505m |
| Dec 31 2019 | US$9m | US$921k | -US$514m |
| Sep 30 2019 | n/a | n/a | -US$535m |
| Jun 30 2019 | n/a | n/a | -US$499m |
| Mar 31 2019 | n/a | n/a | -US$459m |
| Dec 31 2018 | US$59m | US$863k | -US$402m |
| Sep 30 2018 | n/a | n/a | -US$299m |
| Jun 30 2018 | n/a | n/a | -US$280m |
| Mar 31 2018 | n/a | n/a | -US$266m |
| Dec 31 2017 | US$7m | US$651k | -US$270m |
Compensation vs Market: Stephane's total compensation ($USD17.07M) is above average for companies of similar size in the US market ($USD12.88M).
Compensation vs Earnings: Stephane's compensation has been consistent with company performance over the past year.
CEO
Stephane Bancel (51 yo)
13.2yrs
Tenure
US$17,068,514
Compensation
Mr. Stephane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel served as Interim President of Valera LLC. He serves as CEO and Director at Valera LLC.Mr. Bancel serves as a S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 13.2yrs | US$17.07m | 5.48% $ 831.2m | |
| President | no data | US$7.34m | 0.42% $ 63.0m | |
| Chief Financial Officer | 2.3yrs | US$4.32m | 0.0029% $ 436.5k | |
| Chief Legal Officer & Corporate Secretary | 3.5yrs | US$4.31m | 0.0053% $ 804.9k | |
| Chief Technical Operations & Quality Officer | 1.9yrs | no data | no data | |
| Senior VP & Head of Investor Relations | 5.7yrs | no data | no data | |
| Senior Director of Corporate Communications | no data | no data | no data | |
| Chief People & Digital Technology Officer | 5.2yrs | no data | no data | |
| Chief Development Officer | 4.9yrs | no data | no data | |
| Chief Data & AI Officer | no data | no data | no data | |
| Senior VP & Head of Global Regulatory Science | 4.7yrs | no data | no data | |
| Chief Medical Officer | 4.6yrs | no data | no data |
4.7yrs
Average Tenure
49.5yo
Average Age
Experienced Management: MRNA's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 13.8yrs | US$17.07m | 5.48% $ 831.2m | |
| Co-Founder | 14.9yrs | US$663.52k | 0.58% $ 87.6m | |
| Independent Director | 4.4yrs | US$481.27k | 0.00018% $ 27.3k | |
| Member of Scientific Advisory Board | no data | US$461.27k | 2.99% $ 453.4m | |
| Member of Technology Advisory Board | 10.6yrs | no data | no data | |
| Independent Director | 3.8yrs | US$476.25k | 0.00055% $ 83.4k | |
| Member of Technology Advisory Board | 10.6yrs | no data | no data | |
| Independent Non Executive Director | 5yrs | US$481.27k | 0.0054% $ 812.5k | |
| Member of Technology Advisory Board | 10.6yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | 10.6yrs | no data | no data | |
| Member of Technology Advisory Board | 10.6yrs | no data | no data |
10.6yrs
Average Tenure
65yo
Average Age
Experienced Board: MRNA's board of directors are seasoned and experienced ( 10.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Moderna, Inc. is covered by 42 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |